A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate
← catalyst calendarNCT05469854 · readout in 103 d
Sponsored by Cinclus Pharma Holding AB (industry) · CINPHA.ST — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Basic science
Enrollment
121estimated
Sites
1
Country
Sweden
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-07-13 | actual | When the study began enrolling |
| Primary completion | 2026-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2022-07-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pharmacokinetics
- Cardiodynamic ECG
- Safety, and Tolerability
- GERD
Interventions
- Drug: Linaprazan glurate — also filed as X842
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFMeasurement of pharmacokinetic profile of linprazan glurate and linaprazan (AUCinf)
measured Up to 24 hours
Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (AUClast)
measured Up to 24 hours
Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (Cmax)
measured Up to 24 hours
Measurement of pharmacokinetic profile of linprazan glurate and linaprazan (T1/2)
measured Up to 24 hours
Measurement of Cardiodynamic ECG (QTcF)
measured Up to 24 hours
Measurement of Cardiodynamic ECG (heart rate)
measured Up to 24 hours
Measurement of Cardiodynamic ECG (PR interval)
measured Up to 24 hours
Measurement of Cardiodynamic ECG (QRS interval)
measured Up to 24 hours
Measurement of Cardiodynamic ECG (placebo-corrected QTcF)
measured Up to 24 hours
Measurement of Cardiodynamic ECG (placebo-corrected heart rate)
measured Up to 24 hours
Measurement of Cardiodynamic ECG (placebo-corrected PR interval)
measured Up to 24 hours
Measurement of Cardiodynamic ECG (placebo-corrected QRS interval)
measured Up to 24 hours
Measurement of Cardiodynamic ECG (categorical outliers)
measured Up to 24 hours
Measurement of Cardiodynamic ECG (changes of T-wave)
measured Up to 24 hours
Measurement of Cardiodynamic ECG (changes of U-wave)
measured Up to 24 hours
Permalink · CINPHA.ST's whole pipeline · Catalyst calendar · Every registered study · What changed